PPT-Myeloproliferative Neoplasms 2015

Robert J Jacobson MD FACP FRCPC Florida Cancer Specialists Affiliate Professor of Biological Sciences Charles E Schmidt School of Medicine Florida Atlantic University Boca Raton FL 1 Stem Cells and . ODD SEM J ULY DATE DAY DESCRIPTION 1 .07.2015 Wednesday Reopening day 2 .07.2015 Thursday 3 .07.2015 Friday 4 .07.2015 Saturday 5 .07.2015 Sunday 6 .07.2015 Monday 7 .07.2015 Tuesday 8 .07.2015 Wedn Nicolas Novitzky. Leukocytosis. Leukocytosis:. Elevation of leukocyte count above normal for age. Laboratories validate reference ranges in these populations. Neonates: 30 x 10. 9. /L. Adult 10 x10. 9. Kathleen Finnegan . MS MT(ASCP)SH. CM. Stony Brook University. Kathleen.finnegan@stonybrook.edu. Objectives. Describe the classification and characteristics of the MPNs. Discuss the molecular mutations associated with the MPNs and their role in the disease process.. Elizabeth Kollai. RHIT, CCS-P, CHTS-TR. AHIMA Approved ICD-10 Trainer. Only 136 days left before ICD-10 CM. Are you ready?. ICD-10 CM Resources. 2015 ICD-10-CM is available at . http://www.cdc.gov/nchs/icd/icd10cm.htm. Angela Fleischman . Division of hematology/Oncology. MPN are clonal disorders of the hematopoietic stem cell. Myelofibrosis. (MF). Hematopoietic stem cell . (HSC). Essential . Thrombocythemia. (ET). Myeloproliferative Disorders / Neoplasms Intro for the Internist Satish Shanbhag MBBS, MPH Assistant Professor of Medicine and Oncology Johns Hopkins University School of Medicine Objectives Internist focused review of the presentation, diagnostic workup, treatment and prognosis of the common myeloproliferative neoplasms Blood Neoplasms, and Bone Marrow Transplantation. Chronic Myeloproliferative Neoplasms (MPN) . Ph-negative. Marta Sobas. MPN. Ph. CML. Ph (-). Ph (+). PV. ET. MF. AML. Myeloid disorders. MDS. Increased. Dr. Ibrahim. A. Adam. Objectives . Discuss definition, types, . pathophysiology. , clinical features, laboratory findings, complications and treatment of essential . thrombocythsaemia. Discuss definition, . MPNs) . Clinical . Trials. Anthony J. Messina. , . MSc. , CCRP . 1,2 . Quentin E. O’Brien. , MPH. 2*. . Vasily Andrianov. , MD. 1. . Keren R. Moss. , MD. 1*. . Laura Vidal. , MD. After receiving a request from the WTC Clinical Centers of Excellence to review certain myeloid disorders in terms of their status as malignancies, 1 the WTC Health Program has determined that, 2 e g yeloproliferative NeoplasmsInformation Guide https://www.cancersupportcommunity.org/sites/default/files/uploads/learn aboutcancer/cancertypes/Myelofibrosis/fsac_myelofibrosis.pdf o https://www.cancer Statement of Intent and the management options available locally. Review of the Guidelines These guidelines were issued in August 2004 and will be reviewed in August 2006 or sooner CPG Secreta This synopsis has been completed by medical practitioners. It is based on a literature search at the standard of a textbook of medicine and generalist review articles. It is not intended to be a meta- Laura Cortesi. BRCA1/2 Mutations: Cancer Risks. BRCA1. BRCA2. Breast cancer to age 80. 50-85%. 50-85%. Ovarian cancer to age 80. 20-60%. up to 27%. Male . breast. . cancer. . Slight incr. . ~6%. Prostate cancer.